Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
NCT00521586
Completed
This study is to evaluate the safety, tolerability and immune response when 13-valent pneumococcal conjugate vaccine (13vPnC) and the trivalent inactivated flu vaccine (TIV) are given together to healthy adults aged 50-59 years who are naive to 23-valent pneumococcal polysaccharide vaccine (23vPS), or when the vaccines are given 1 month apart. It will also evaluate the immune response to 13vPnC once per year for 4 years and then to a second dose of 13vPnC given 5 years after the first dose.
Gender:
ALL
Ages:
Between 50 years and 59 years
Trial Updated:
04/07/2015
Locations: Clinical Research Advantage, Inc., Chandler, Arizona
Conditions: Influenza
Register for Updates
A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults
NCT01427309
Completed
The aim of this study is to determine the efficacy of Fluzone High-Dose compared to standard dose Fluzone for laboratory-confirmed or culture-confirmed influenza caused by influenza types/subtypes that are similar (for laboratory-confirmed) or antigenically similar (for culture-confirmed) to those contained in the respective annual vaccine formulations. Primary Objective: * To compare the clinical efficacy of Fluzone High-Dose to that of Fluzone in elderly adults, with respect to laboratory-co... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/30/2015
Locations: Not set, Chandler, Arizona +9 locations
Conditions: Influenza
Register for Updates
Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)
NCT01773928
Completed
The purpose of this study is to determine if a Vero cell-derived trivalent seasonal influenza vaccine produced by the modified manufacturing process: 1. induces immune responses comparable to that produced by the current manufacturing process 2. has an acceptable safety profile compared to a licensed trivalent seasonal influenza vaccine 3. demonstrates consistency of immune response among three different lots.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2014
Locations: East Valley Family Physicians, PLC, Chandler, Arizona
Conditions: Influenza
Register for Updates
A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
NCT00953524
Completed
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine. Primary Objectives: * To describe the immunogenicity of the candidate vaccines after each injection. * To describe the safety of the candidate vaccines after each injection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2014
Locations: Not set, Chandler, Arizona +1 locations
Conditions: Influenza, Swine-origin A/H1N1 Influenza
Register for Updates
Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
NCT00775450
Completed
This is a multi-center study designed to evaluate the safety and immunogenicity of a Fluzone revaccination in elderly adults aged ≥ 65 years. Primary Objective: To describe the safety profile for all subjects. Secondary Objective: To describe immunogenicity 28 days following revaccination with one of three Fluzone formulations.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
12/05/2013
Locations: Not set, Chandler, Arizona +3 locations
Conditions: Influenza, Orthomyxovirus Infection, Myxovirus Infection
Register for Updates
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
NCT00574548
Completed
The objective of this study is to compare the safety, tolerability and immunologic response to a dose of 23vPS or 13vPnC given one year after either 13vPnC or 23vPS in subjects that have never received a previous dose of 23vPS.
Gender:
ALL
Ages:
Between 60 years and 64 years
Trial Updated:
07/18/2011
Locations: Pfizer Investigational Site, Chandler, Arizona
Conditions: Pneumococcal Vaccines
Register for Updates